KR20240151808A - 구사시티닙의 고체 상태 형태 - Google Patents

구사시티닙의 고체 상태 형태 Download PDF

Info

Publication number
KR20240151808A
KR20240151808A KR1020247030857A KR20247030857A KR20240151808A KR 20240151808 A KR20240151808 A KR 20240151808A KR 1020247030857 A KR1020247030857 A KR 1020247030857A KR 20247030857 A KR20247030857 A KR 20247030857A KR 20240151808 A KR20240151808 A KR 20240151808A
Authority
KR
South Korea
Prior art keywords
theta
degrees
gusacitinib
crystalline
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247030857A
Other languages
English (en)
Korean (ko)
Inventor
아난타 라즈모한 무투사미
아밋 싱
찬찰 싱
프라탑 렌가라즈
Original Assignee
테바 파마슈티컬스 인터내셔널 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테바 파마슈티컬스 인터내셔널 게엠베하 filed Critical 테바 파마슈티컬스 인터내셔널 게엠베하
Publication of KR20240151808A publication Critical patent/KR20240151808A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247030857A 2022-02-23 2023-02-23 구사시티닙의 고체 상태 형태 Pending KR20240151808A (ko)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
IN202211009506 2022-02-23
IN202211009506 2022-02-23
IN202211028117 2022-05-16
IN202211028117 2022-05-16
IN202211031922 2022-06-03
IN202211031922 2022-06-03
IN202211053997 2022-09-21
IN202211053997 2022-09-21
IN202311006675 2023-02-02
IN202311006675 2023-02-02
IN202311007408 2023-02-06
IN202311007408 2023-02-06
PCT/US2023/013668 WO2023164024A1 (en) 2022-02-23 2023-02-23 Solid state forms of gusacitinib

Publications (1)

Publication Number Publication Date
KR20240151808A true KR20240151808A (ko) 2024-10-18

Family

ID=85640884

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030857A Pending KR20240151808A (ko) 2022-02-23 2023-02-23 구사시티닙의 고체 상태 형태

Country Status (6)

Country Link
US (1) US20250171448A1 (https=)
EP (1) EP4482836A1 (https=)
JP (1) JP2025506783A (https=)
KR (1) KR20240151808A (https=)
CA (1) CA3244694A1 (https=)
WO (1) WO2023164024A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202510870A (zh) * 2023-07-27 2025-03-16 美商自由生物有限公司 Jak/syk抑制劑之組合物及固體形式
WO2025020171A1 (en) * 2023-07-27 2025-01-30 Libertas Bio, Inc. Crystalline forms of a jak/syk inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2748166T3 (pl) * 2011-08-23 2019-05-31 Asana Biosciences Llc Związki pirimido-pirydazynonowe oraz ich zastosowanie
WO2018187294A1 (en) * 2017-04-03 2018-10-11 Asana Biosciences, Llc Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
EP3875078A1 (en) * 2020-03-06 2021-09-08 Dompe' Farmaceutici S.P.A. Compounds for the treatment of covid-19

Also Published As

Publication number Publication date
WO2023164024A1 (en) 2023-08-31
EP4482836A1 (en) 2025-01-01
JP2025506783A (ja) 2025-03-13
US20250171448A1 (en) 2025-05-29
CA3244694A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
US12509456B2 (en) Solid state forms of ripretinib
US20240199578A1 (en) Solid state forms of zavegepant and process for preparation thereof
KR20240151808A (ko) 구사시티닙의 고체 상태 형태
EP4096790B1 (en) Solid state forms of asciminib and processes for the preparation thereof
US20240352014A1 (en) Solid state forms of vericiguat and process for preparation thereof
US11427533B2 (en) Crystalline polymorphs of bardoxolone methyl
US20210253529A1 (en) New crystalline polymorphs of rivoceranib and rivoceranib mesylate
US20230103724A1 (en) Solid state forms of avapritinib and process for preparation thereof
US20220153744A1 (en) Solid state forms of acalabrutinib
WO2021216628A1 (en) Solid state forms of trifarotene and process for preparation thereof
EP4051659B1 (en) Solid state forms of fezagepras and process for preparation thereof
US20240294537A1 (en) SOLID STATE FORMS OF 4-[[4-(4-CHLOROANILINO)FURO[2,3-d]PYRIDAZIN-7-yl]OXYMETHYL]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND SALT THEREOF
US20240279167A1 (en) Crystalline polymorphs of rigosertib sodium
US20240246914A1 (en) Solid state form of centanafadine hcl and process for preparation thereof
US12391708B2 (en) Crystalline Lorlatinib : fumaric acid and solid state form thereof
US20230322786A1 (en) Solid state forms of at-001 and process for preparation thereof
CN118974054A (zh) 古沙替尼的固态形式
WO2024180476A1 (en) Solid state forms of anlotinib and process for preparation thereof
US20230373998A1 (en) Solid state forms of lorecivivint
JP2026501777A (ja) ブリラロキサジンの固体形態及びブリラロキサジン塩
EP4665732A1 (en) Salts and solid forms of elenestinib
EP4214195A1 (en) Solid state forms of gefapixant and process for preparation thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000